Mené en Corée du Sud sur 974 patients atteints d'un adénocarcinome gastrique de stade localement avancé, cet essai de phase III évalue la non infériorité, du point de vue du taux de survie sans récidive à 3 ans, d'une gastrectomie subtotale laparoscopique avec lymphadénectomie D2 par rapport à une chirurgie par voie ouverte

Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial

Hyung, Woo Jin ; Yang, Han-Kwang ; Park, Young-Kyu ; Lee, Hyuk-Joon ; An, Ji Yeong ; Kim, Wook ; Kim, Hyoung-Il ; Kim, Hyung-Ho ; Ryu, Seung Wan ; Hur, Hoon ; Kim, Min-Chan ; Kong, Seong-Ho ; Cho, Gyu Seok ; Kim, Jin-Jo ; Park, Do Joong ; Ryu, Keun Won ; Kim, Young Woo ; Kim, Jong Won ; Lee, Joo-Ho ; Han, Sang-Uk

PURPOSE : It is unclear whether laparoscopic distal gastrectomy for locally advanced gastric cancer is oncologically equivalent to open distal gastrectomy. The noninferiority of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer compared with open surgery in terms of 3-year relapse-free survival rate was evaluated. PATIENTS AND METHODS : A phase III, open-label, randomized controlled trial was conducted for patients with histologically proven locally [...]

Mené en Chine sur 214 patients atteints d'un cancer gastrique de stade I (âge moyen : environ 59 et 60 ans selon le groupe), cet essai multicentrique compare, du point de vue des taux de complications et des taux de décès, l'intérêt d'une gastrectomie totale laparoscopique et d'une gastrectomie totale par voie ouverte

Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial

Liu, Fenglin ; Huang, Changming ; Xu, Zekuan ; Su, Xiangqian ; Zhao, Gang ; Ye, Jianxin ; Du, Xiaohui ; Huang, Hua ; Hu, Jiankun ; Li, Guoxin ; Yu, Peiwu ; Li, Yong ; Suo, Jian ; Zhao, Naiqing ; Zhang, Wei ; Li, Haojie ; He, Hongyong ; Sun, Yihong ; for the Chinese Laparoscopic Gastrointestinal Surgery Study Group

Importance : The safety of laparoscopic total gastrectomy (LTG) for the treatment of gastric cancer remains uncertain given the lack of high-level clinical evidence. Objective : To compare the safety of LTG for clinical stage I gastric cancer with that of conventional open total gastrectomy (OTG). Design, Setting, and Participants : The Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group CLASS02 study was a prospective, multicenter, open-label, noninferiority, randomized clinical [...]

Mené sur 520 patientes atteintes d'un cancer du sein de stade précoce (durée médiane de suivi : 10,7 ans), cet essai de phase III évalue l'efficacité, du point de vue du taux cumulé de récidive ipsilatérale à 10 ans, de la survie spécifique et de la survie globale, et la toxicité d'une irradiation partielle accélérée du sein par rapport à une radiothérapie de l'ensemble du sein

Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial

Meattini, Icro ; Marrazzo, Livia ; Saieva, Calogero ; Desideri, Isacco ; Scotti, Vieri ; Simontacchi, Gabriele ; Bonomo, Pierluigi ; Greto, Daniela ; Mangoni, Monica ; Scoccianti, Silvia ; Lucidi, Sara ; Paoletti, Lisa ; Fambrini, Massimiliano ; Bernini, Marco ; Sanchez, Luis ; Orzalesi, Lorenzo ; Nori, Jacopo ; Bianchi, Simonetta ; Pallotta, Stefania ; Livi, Lorenzo

PURPOSE : To report the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) Florence phase III trial comparing whole-breast irradiation (WBI) to APBI in early-stage breast cancer. PATIENTS AND METHODS : The primary end point was to determine the 5-year difference in ipsilateral breast tumor recurrence (IBTR) between 30 Gy in 5 once-daily fractions (APBI arm) and 50 Gy in 25 fractions with a tumor bed boost (WBI arm) after [...]

Mené sur 1 815 patientes atteintes d'un cancer invasif du sein (durée médiane de suivi : 52,7 mois), cet essai évalue l'effet de deux types de chirurgie axillaire (biopsie du ganglion sentinelle, curage des ganglions axillaires), en combinaison ou non avec une irradiation des ganglions lymphatiques régionaux, sur le risque de lymph

Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer–Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial

Naoum, George E. ; Roberts, Sacha ; Brunelle, Cheryl L. ; Shui, Amy M. ; Salama, Laura ; Daniell, Kayla ; Gillespie, Tessa ; Bucci, Loryn ; Smith, Barbara L. ; Ho, Alice Y. ; Taghian, Alphonse G.

PURPOSE : To independently evaluate the impact of axillary surgery type and regional lymph node radiation (RLNR) on breast cancer–related lymphedema (BCRL) rates in patients with breast cancer. PATIENTS AND METHODS : From 2005 to 2018, 1,815 patients with invasive breast cancer were enrolled in a lymphedema screening trial. Patients were divided into the following 4 groups according to axillary surgery approach: sentinel lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection [...]

Mené sur 2 298 patientes âgées de 45 ans ou plus et atteintes d'un carcinome canalaire invasif du sein (taille inférieure ou égale à 3,5 cm ; stade maximal : cN0-N1), cet essai international évalue, du point de vue du taux de récidive locale à 5 ans et de la survie à long terme, la non infériorité d'une radiothérapie réalisée durant la lumpectomie par rapport à une radiothérapie externe postopératoire de l'ensemble du sein

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

Vaidya, Jayant S ; Bulsara, Max ; Baum, Michael ; Wenz, Frederik ; Massarut, Samuele ; Pigorsch, Steffi ; Alvarado, Michael ; Douek, Michael ; Saunders, Christobel ; Flyger, Henrik L ; Eiermann, Wolfgang ; Brew-Graves, Chris ; Williams, Norman R ; Potyka, Ingrid ; Roberts, Nicholas ; Bernstein, Marcelle ; Brown, Douglas ; Sperk, Elena ; Laws, Siobhan ; Sütterlin, Marc ; Corica, Tammy ; Lundgren, Steinar ; Holmes, Dennis ; Vinante, Lorenzo ; Bozza, Fernando ; Pazos, Montserrat ; Le Blanc-Onfroy, Magali ; Gruber, Gunther ; Polkowski, Wojciech ; Dedes, Konstantin J ; Niewald, Marcus ; Blohmer, Jens ; McCready, David ; Hoefer, Richard ; Kelemen, Pond ; Petralia, Gloria ; Falzon, Mary ; Joseph, David J ; Tobias, Jeffrey S

Objective: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer. Design: Prospective, open label, randomised controlled clinical trial. Setting: 32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada. Participants: 2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in [...]

Mené en Chine sur 734 patientes atteintes d'un cancer invasif du sein de stade T1-2N0-3 et ayant subi une chirurgie conservatrice (durée médiane de suivi : 73,5 mois), cet essai multicentrique évalue la non infériorité, du point de vue de la récidive locale à 5 ans, d'une radiothérapie hypofractionnée par rapport à une radiothérapie fractionnée conventionnelle

Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China

Wang, Shu-Lian ; Fang, Hui ; Hu, Chen ; Song, Yong-Wen ; Wang, Wei-Hu ; Jin, Jing ; Liu, Yue-Ping ; Ren, Hua ; Liu, Juan ; Li, Gao-Feng ; Du, Xiang-Hui ; Tang, Yu ; Jing, Hao ; Ma, Yu-Chao ; Huang, Zhou ; Chen, Bo ; Tang, Yuan ; Li, Ning ; Lu, Ning-Ning ; Qi, Shu-Nan ; Yang, Yong ; Sun, Guang-Yi ; Liu, Xin-Fan ; Li, Ye-Xiong

PURPOSE : No randomized trials have compared hypofractionated radiotherapy (HFRT) with conventional fractionated radiotherapy (CFRT) after breast-conserving surgery in the Asian population. This study aimed to determine whether a 3.5-week schedule of HFRT is noninferior to a standard 6-week schedule of CFRT in China. PATIENTS AND METHODS : Patients from 4 Chinese institutions who had undergone breast-conserving surgery and had T1-2N0-3 invasive breast cancers participated this study. Patients [...]

Menée à l'aide de quatre modèles murins de cancer, cette étude met en évidence un mécanisme par lequel l'inosine issue de bactéries intestinales régule la réponse aux inhibiteurs de point de contrôle immunitaire

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Mager, Lukas F. ; Burkhard, Regula ; Pett, Nicola ; Cooke, Noah C. A. ; Brown, Kirsty ; Ramay, Hena ; Paik, Seungil ; Stagg, John ; Groves, Ryan A. ; Gallo, Marco ; Lewis, Ian A. ; Geuking, Markus B. ; McCoy, Kathy D.

Several species of intestinal bacteria have been associated with enhanced efficacy of checkpoint blockade immunotherapy, but the underlying mechanisms by which the microbiome enhances anti-tumor immunity is unclear. Here, we isolated three bacterial species, including Bifidobacterium pseudolongum, Lactobacillus johnsonii and Olsenella species, that significantly enhanced efficacy of immune checkpoint inhibitors in four mouse models of cancer. We found that intestinal B. pseudolongum modulated [...]

Menée à l'aide de modèles murins, cette étude met en évidence l'activité antitumorale d'un agoniste non nucléotidique de STING administré par voie orale

An orally available non-nucleotide STING agonist with antitumor activity

Pan, Bo-Sheng ; Perera, Samanthi A. ; Piesvaux, Jennifer A. ; Presland, Jeremy P. ; Schroeder, Gottfried K. ; Cumming, Jared N. ; Trotter, B. Wesley ; Altman, Michael D. ; Buevich, Alexei V. ; Cash, Brandon ; Cemerski, Saso ; Chang, Wonsuk ; Chen, Yiping ; Dandliker, Peter J. ; Feng, Guo ; Haidle, Andrew ; Henderson, Timothy ; Jewell, James ; Kariv, Ilona ; Knemeyer, Ian ; Kopinja, Johnny ; Lacey, Brian M. ; Laskey, Jason ; Lesburg, Charles A. ; Liang, Rui ; Long, Brian J. ; Lu, Min ; Ma, Yanhong ; Minnihan, Ellen C. ; O’Donnell, Greg ; Otte, Ryan ; Price, Laura ; Rakhilina, Larissa ; Sauvagnat, Berengere ; Sharma, Sharad ; Tyagarajan, Sriram ; Woo, Hyun ; Wyss, Daniel F. ; Xu, Serena ; Bennett, David Jonathan ; Addona, George H.

Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity. The development of synthetic STING agonists is therefore being pursued as a strategy for cancer therapy, but the inherent instability of dinucleotides has limited current efforts. Pan et al. and Chin et al. identified stable STING agonists that act in a “closed” conformation similar to the natural STING ligand, cyclic guanosine monophosphate–adenosine [...]

Mené sur 258 patients atteints d’une tumeur stromale gastrointestinale de stade avancé, cet essai de phase I évalue la dose maximale tolérée et l’efficacité, du point de vue du taux de réponse objective, du riprétinib, un inhibiteur de tyrosine kinase KIT et PDGFRA

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Filip Janku, Albiruni R. Abdul Razak, Ping Chi (et al.)

PURPOSE : In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations. PATIENTS AND METHODS : This first-in-human, to our knowledge, phase I study of ripretinib (ClinicalTrials.gov identifier: NCT02571036) included a dose-escalation phase and subsequent expansion [...]

Mené sur 241 patients atteints d’un cancer colorectal et présentant des métastases hépatiques avec mutation du gène RAS, cet essai randomisé évalue l’efficacité, du point de vue du taux de résection R0 des métastases, et la toxicité de l’ajout du bévacizumab à un traitement de première ligne de type mFOLOFOX6

Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial

Wentao Tang, Li Ren, Qinghai Ye (et al.)

PURPOSE : To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver metastases. METHODS : From October 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone (arm B). The resectability of liver metastases was determined by a local [...]

Mené sur 35 patients atteints d’un cancer et présentant la mutation V600E du gène BRAF (âge médian : 59 ans), cet essai à bras unique évalue l’efficacité, du point de vue du taux de réponse objective, d’un traitement combinant dabrafénib et tramétinib

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

April K. S. Salama, MD1 ; Shuli Li, PhD2 ; Erin R. Macrae (et al.)

PURPOSE : BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored a BRAFV600 mutation. PATIENTS AND METHODS : EAY131-H is an open-label, single-arm study. Patients with melanoma, thyroid, or colorectal [...]

A partir d’une revue systématique de la littérature (37 essais de phase II ou III incluant un total de 23?760 patients), cette méta-analyse évalue l’association entre l’âge, le sexe et l’efficacité, du point de vue de la survie globale, des immunothérapies chez des patients atteints d’un cancer de stade avancé

Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials : A Systematic Review and Meta-analysis

Fang Yang, Svetomir N. Markovic, Julian R. Molina (et al.)

Importance : Sex, age, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) may affect immune response. However, the association of these factors with the survival benefit of cancer immunotherapy with immune checkpoint inhibitors (ICIs) remains unclear. Objective : To assess the potential sex, age, and ECOG PS differences of immunotherapy survival benefit in patients with advanced cancer. Data Sources : PubMed, Web of Science, Embase, and Scopus were searched from inception to [...]

Menée aux Etats-Unis à partir de données portant sur 17 patients ayant reçu une greffe d’organe (foie, rein ou cœur) et atteints d’un cancer de stade métastatique, cette étude analyse la toxicité et la survie associées à l'utilisation d'inhibiteurs de points de contrôle immunitaire

Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis

Itunu Owoyemi, Lisa E. Vaughan, Collin M. Costello (et al.)

Background : Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but to the authors' knowledge, limited data exist regarding the safety and efficacy of these agents in transplant recipients. Herein, the authors have reported their experience with 17 patients who were treated with ICIs for metastatic malignancies after undergoing solid organ transplantation. Methods : Data were abstracted for solid organ transplant recipients who received ICIs for the treatment of malignancy [...]

Mené sur 62 patients atteints d’une tumeur solide de stade avancé, cet essai de phase I évalue la dose maximale tolérée de LY3127804 (un anticorps anti-angiopoïétine-2), dispensé en monothérapie ou combiné au ramucirumab

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

Juan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos (et al.)

Background : This is the first-in-human study of novel anti-angiopoietin-2 (Ang-2) monoclonal antibody LY3127804 as monotherapy and in combination with ramucirumab in advanced solid tumours. Methods : Patients received intravenous LY3127804 monotherapy (4, 8, 12, 16, 20 and 27?mg/kg) in part A; LY3127804 (8, 12, 16, 20 and 27?mg/kg) with 8?mg/kg ramucirumab in part B; and LY3127804 (20?mg/kg) with 12?mg/kg ramucirumab in part C. Treatments were administered every 2 weeks (Q2W) during 28-day [...]

Mené sur 73 patients atteints d’une tumeur solide de stade avancé ou récidivante, cet essai de phase I/IIA évalue la dose maximale tolérée de BAL101553 (lisavanbuline), un composé ciblant les microtubules et dispensé par voie intraveineuse

Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

Rebecca Kristeleit, Jeffry Evans, L. Rhoda Molife (et al.)

Background : BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. Methods : This two-part, open-label, phase 1/2a study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of 2-h infusion of BAL101553 in adults with advanced or recurrent solid tumours. The MTD was determined using a modified accelerated titration [...]

Mené sur un total de 50 patients atteints d’une leucémie lymphoïde chronique, cet essai de phase II évalue l’efficacité, du point de vue du taux de rémission complète, et la toxicité d’un traitement combinant obinutuzumab, ibrutinib, et vénétoclax, dispensé en première ligne (25 patients ; durée médiane de suivi : 24,2 mois) ou après l’échec de plusieurs lignes de traitements (25 patients ; durée médiane de suivi : 21,5 mois)

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, Ying Huang, Amy S. Ruppert (et al.)

PURPOSE : The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS : This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy [...]

Mené sur 1 562 patients âgés de 1 à 31 ans atteints d’une leucémie lymphoblastique aiguë à cellules T récemment diagnostiquée, cet essai de phase III évalue l’efficacité, du point de vue de la survie globale, de la survie sans événement et de la survie sans maladie à 5 ans, et la toxicité de l’ajout de la nélarabine à une chimiothérapie de type aBFM (régime Berlin-Frankfurt-Münster dans sa version augmentée)

Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Kimberly P. Dunsmore, Stuart S. Winter, Meenakshi Devidas (et al.)

PURPOSE : Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. PATIENTS AND METHODS : From 2007 to 2014, Children’s Oncology Group trial AALL0434 (ClinicalTrials.gov identifier: NCT00408005) enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial [...]

Mené sur 17 patients atteints d’une leucémie myéloïde aiguë récidivante (enfants, adolescents et jeunes adultes), cet essai de phase I évalue la dose maximale tolérée du panobinostat et analyse ses caractéristiques pharmacocinétiques et pharmacodynamiques

Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia

Seth E. Karol, Todd M. Cooper, Paul E. Mead (et al.)

Background : Novel therapies are urgently needed for pediatric patients with relapsed acute myeloid leukemia (AML). Methods : To determine whether the histone deacetylase inhibitor panobinostat could be safely given in combination with intensive chemotherapy, a phase 1 trial was performed in which 17 pediatric patients with relapsed or refractory AML received panobinostat (10, 15, or 20 mg/m2) before and in combination with fludarabine and cytarabine. Results : All dose levels were tolerated, [...]

Mené sur 21 patients atteints d’un lymphome extra-ganglionnaire à cellules T/NK réfractaire ou récidivant, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse complète, et la toxicité de l’avélumab

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho (et al.)

This study aimed to assess the efficacy and safety of treatment with avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL). In this phase II trial, 21 patients with relapsed or refractory ENKTL were treated with 10 mg/kg of avelumab on days 1 and 15 of a 28-day cycle (ClinicalTrials.gov Identifier: NCT03439501). The primary end point was the complete response (CR) rate based on the best [...]

Mené sur 303 patientes atteintes d’un carcinome séreux de l’ovaire de faible grade, récidivant ou persistant, cet essai de phase II compare l’efficacité, du point de vue de la survie sans progression, et la toxicité du binimétinib et d’une chimiothérapie choisie par le médecin, après l’échec d’une à trois lignes de chimiothérapies

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee (et al.)

PURPOSE : Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity across multiple cancers, in LGSOC. METHODS : This was a 2:1 randomized study of binimetinib (45 mg twice daily) versus physician’s choice chemotherapy (PCC). Eligible patients had recurrent [...]

Mené sur 564 patientes atteintes d'un carcinome ovarien récidivant, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression ajustée sur la qualité et de la durée sans symptômes ni toxicité, du rucaparib en traitement d'entretien

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Amit M. Oza ; Domenica Lorusso ; Carol Aghajanian ; Ana Oaknin ; Andrew Dean ; Nicoletta Colombo ; Johanne I. Weberpals ; Andrew R. Clamp ; Giovanni Scambia ; Alexandra Leary ; Robert W. Holloway ; Margarita Amenedo Gancedo ; Peter C. Fong ; Jeffrey C. Goh ; David M. O’Malley ; Deborah K. Armstrong ; Susana Banerjee ; Jesus García-Donas ; Elizabeth M. Swisher ; David Cella ; Juliette Meunier ; Sandra Goble ; Terri Cameron ; Lara Maloney ; Ann-Christin Mörk ; Josh Bedel ; Jonathan A. Ledermann ; Robert L. Coleman

PURPOSE : To investigate quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of the phase III ARIEL3 study of rucaparib maintenance treatment versus placebo. PATIENTS AND METHODS : Patients with platinum-sensitive, recurrent ovarian carcinoma were randomly assigned to rucaparib (600 mg twice per day) or placebo. QA-PFS was calculated as progression-free survival function × the 3-level version of [...]

Mené sur 275 patients atteints d’un cancer du poumon non à petites cellules ALK+, cet essai de phase III compare l’efficacité, du point de vue de la survie sans progression, et la toxicité du brigatinib et du crizotinib en traitement de première ligne (durée médiane de suivi : 24,9 mois)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn (et al.)

PURPOSE : Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results of the second prespecified [...]

Mené sur 115 patients atteints d’un cancer de la prostate résistant à la castration, de stade métastatique et présentant des altérations des gènes BRCA, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse objective, et la toxicité du rucaparib

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Wassim Abida, Akash Patnaik, David Campbell (et al.)

PURPOSE : BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS : We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based [...]

Mené sur 17 patients atteints d'un cancer du rectum de stade II ou III, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse complète, d'un traitement néoadjuvant de type FLOFOX7 modifié en combinaison avec le bévacizumab

Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer

Barzi, Afsaneh ; Choi, April ; Tsao-Wei, Denice ; Iqbal, Syma ; El-khoueiry, Anthony ; Agafitei, Dana Raluca ; Cologne, Kyle G ; Lenz, Heinz-Josef

Background : Combination chemotherapy in lieu of radiation in rectal adenocarcinoma is under exploration in multiple trials. We evaluated the efficacy of neoadjuvant FOLFOX + bevacizumab in patients (pts) with clinical stage II and III disease. Methods : Pts received six cycles of bevacizumab (5 mg/kg) and modified FOLFOX7 (oxaliplatin 85 mg/m2, leucovorin 20 mg/m2, and fluorouracil [5-FU] 2,400 mg/m2). Surgical resection was performed 6–8 weeks after completion of treatment and upon [...]

Menée à partir des données portant sur 1 697 patients atteints d’un cancer colorectal non résécable de stade métastatique et inclus dans 5 essais, cette méta-analyse compare l’efficacité, du point de vue de la survie globale, et la toxicité d’une chimiothérapie de type FOLFOXIRI (triplet) et de doublets de chimiothérapie (de type FOLFOX ou FOLFIRI), en combinaison avec le bévacizumab en traitement de première ligne (durée médiane de suivi : 39,9 mois)

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Chiara Cremolini, Carlotta Antoniotti, Alexander Stein (et al.)

PURPOSE : A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have investigated this regimen had primary end points other than OS. To test OS with higher power and to explore the interaction of treatment effect with main patient and disease characteristics, we performed an individual patient data (IPD) [...]

A partir d’une revue de la littérature (8 essais, 2 799 patients), cette méta-analyse compare la toxicité de différents inhibiteurs de CDK4/6 (palbociclib, ribociclib et abémaciclib) chez des patientes atteintes d’un cancer métastatique du sein

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis

Alexandra Desnoyers, Michelle B. Nadler, Vikaash Kumar (et al.)

Background : Palbociclib, ribociclib and abemaciclib have all been approved in combination with endocrine therapy in hormone-receptor positive, HER2 negative metastatic breast cancer. While the efficacy of these drugs appears similar, differences in safety and tolerability are apparent. Methods : We searched PubMed and ASCO, ESMO and SABCS proceedings to identify randomized trials of palbociclib, ribociclib and abemaciclib. Data on common and serious adverse events (AE) were extracted for each [...]

A partir d'une revue de la littérature, cette étude fait le point sur l'utilisation et l'efficacité des différents traitements anticancéreux, et particulièrement les traitement systémiques adjuvants, chez les hommes atteints d'un cancer du sein de stade précoce

Adjuvant treatment of early male breast cancer

Corti, Chiara ; Crimini, Edoardo ; Criscitiello, Carmen ; Trapani, Dario ; Curigliano, Giuseppe

Purpose of review : Male breast cancer (MaBC) is a rare disease, and some challenges exist in its management because current treatment recommendations are extrapolated from trials that mostly excluded men. This review will revise all available data that could improve the treatment of MaBC, with a special focus on adjuvant systemic treatments. Recent findings : To date, men with hormone receptor-positive breast cancer, who are candidates for adjuvant endocrine therapy, should be offered [...]

Mené sur 431 patientes atteintes d’un cancer du sein HER2- de stade avancé et présentant des mutations constitutionnelles BRCA1/2, cet essai de phase III compare l’efficacité, du point de vue de la survie globale, et la toxicité du talazoparib et d’une chimiothérapie choisie par le médecin (durées médianes de suivi : 44,9 et 36,8 mois)

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

J.K.Litton, S.A.Hurvitz, L.A.Mina (et al.)

Patients and methods : This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician’s choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments. Results : 431 patients were randomized (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By September 30, 2019, [...]

Mené sur 647 patientes atteintes d’un cancer du sein triple négatif (âge moyen : 51 ans), cet essai de phase III compare l’efficacité, du point de vue de la survie sans maladie, et la toxicité du traitement adjuvant standard (cyclophosphamide, épirubicine et fluorouracile suivi par du docétaxel) et d’un traitement adjuvant combinant paclitaxel et carboplatine (durée médiane de suivi : 62 mois)

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer :A Phase 3 Randomized Clinical Trial

Ke-Da Yu, Fu-Gui Ye, Min He (et al.)

Importance : The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective : To compare 6 cycles of paclitaxel plus carboplatin (PCb) with a standard-dose regimen of 3 cycles of cyclophosphamide, epirubicin, and fluorouracil followed by 3 cycles of docetaxel (CEF-T). Design, Setting, and Participants : This [...]

Mené sur 355 patientes atteintes d’un cancer du sein HR+ HER2+ de stade métastatique après la ménopause, cet essai de phase III évalue l’efficacité, du point de vue de la survie sans propgression, et la toxicité de l’ajout du lapatinib à un traitement combinant trastuzumab et inhibiteur de l’aromatase

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Stephen R. D. Johnston, PhD1 ; Roberto Hegg, MD, PhD2 ; Seock-Ah Im (et al.)

PURPOSE : Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior [...]

Mené sur 34 patientes atteintes d’un cancer métastatique de sein et porteuses de mutations constitutionnelles BRCA, cet essai de phase I/II évalue la dose maximale tolérée et l’efficacité, du point de vue du taux de contrôle de la maladie en semaine 12, de l’olaparib en combinaison avec le durvalumab

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M Domchek, Sophie Postel-Vinay, Prof Seock-Ah Im (et al.)

Background : Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer. Methods : The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in solid tumours. Patients were enrolled into four initial [...]

Mené sur 75 patients atteints d’un cancer urothélial de stade métastatique et résistant aux sels de platine, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse objective, et la toxicité de l’ajout de l’acalabrutinib au pembrolizumab

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer

Tian Zhang, Michael R. Harrison, Peter H. O'Donnell (et al.)

Background : Inhibition of the programmed cell death protein 1 (PD?1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid?derived suppressor cells (MDSCs) and improve T?cell activation. Methods : The Randomized Phase 2 Trial of Acalabrutinib and Pembrolizumab Immunotherapy Dual Checkpoint Inhibition in Platinum?Resistant [...]

Cet article passe en revue les stratégies thérapeutiques pour prendre en charge les patients atteints d’un cancer de la vessie de stade avancé avec envahissement musculaire

Treatment of muscle-invasive and advanced bladder cancer in 2020

Vaibhav G. Patel, William K. Oh, Matthew D. Galsky

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle?invasive and advanced bladder cancer has primarily consisted of platinum?based chemotherapy. Over the past 10 years, innovations in sequencing technologies have led to rapid genomic characterization of bladder cancer, deepening our understanding of bladder cancer pathogenesis and exposing potential therapeutic vulnerabilities. On the basis of its high mutational burden, [...]

Mené sur 13 patients atteints d’un carcinome urothélial de stade métastatique résistant aux sels de platine, cet essai de phase II évalue l’efficacité, du point de vue du taux de survie sans progression à 2 mois, et la toxicité du buparlisib

A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma

Victor McPherson, Brendan Reardon, Aravind Bhayankara (et al.)

Background : The phosphatidyl 3?inositol kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway frequently is activated in patients with urothelial carcinoma (UC). In the current study, the authors performed a phase 2 study evaluating the efficacy of the pan?isoform class I PI3K inhibitor buparlisib in patients with platinum?refractory metastatic UC. Methods : Two cohorts were recruited: an initial genetically unselected cohort and a subsequent expansion cohort of patients with [...]

Mené sur 43 patients atteints d’un cancer des voies biliaires présentant la mutation V600E du gène BRAF, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse globale, et la toxicité d’un traitement combinant dabrafénib et tramétinib (durée médiane de suivi : 10 mois)

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah, Prof Ulrik Lassen, Elena Élez (et al.)

Background : Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabrafenib and trametinib has shown activity in several BRAF V600E-mutated cancers. We aimed to assess the activity and safety of dabrafenib and trametinib combination therapy in patients with BRAF V600E-mutated biliary tract cancer. Methods : This study is [...]

Mené sur 62 patients atteints d'un carcinome épidermoïde métastatique de la tête et du cou, cet essai de phase II évalue l'intérêt, du point de vue du taux de réponse objective au niveau des lésions cancéreuses non irradiées, d'ajouter une radiothérapie corporelle stéréotaxique au nivolumab

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

McBride, Sean ; Sherman, Eric ; Tsai, C. Jillian ; Baxi, Shrujal ; Aghalar, Jahan ; Eng, Juliana ; Zhi, Wanqing Iris ; McFarland, Daniel ; Michel, Loren Scott ; Young, Robert ; Lefkowitz, Robert ; Spielsinger, Daniel ; Zhang, Zhigang ; Flynn, Jessica ; Dunn, Lara ; Ho, Alan ; Riaz, Nadeem ; Pfister, David ; Lee, Nancy

PURPOSE : The objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically with anti–PD-1 therapy to improve response through the abscopal effect. PATIENTS AND METHODS : We conducted a single-center, randomized, phase II trial of nivolumab (anti–PD-1 therapy) versus nivolumab plus stereotactic body [...]

Cet article passe en revue les différentes immunothérapies actuellement utilisées pour traiter un cancer du poumon ou un carcinome épidermoïde de la tête et du cou, puis identifie les axes de recherche

An update on the immune landscape in lung and head and neck cancers

Carlisle, Jennifer W. ; Steuer, Conor E. ; Owonikoko, Taofeek K. ; Saba, Nabil F.

Immunotherapy has dramatically changed the treatment landscape for patients with cancer. Programmed death–ligand 1/programmed death‐1 checkpoint inhibitors have been in the forefront of this clinical revolution. Currently, there are 6 US Food and Drug Administration‐approved checkpoint inhibitors for approximately 18 different histologic types of cancer. Lung cancer and head and neck squamous cell carcinoma (HNSCC) are 2 diseases that have led the way in the development of immunotherapy. [...]

Cet article analyse les implications potentielles de l'intelligence artificielle dans le processus de radiothérapie

Artificial intelligence in radiation oncology

Huynh, Elizabeth ; Hosny, Ahmed ; Guthier, Christian ; Bitterman, Danielle S. ; Petit, Steven F. ; Haas-Kogan, Daphne A. ; Kann, Benjamin ; Aerts, Hugo J. W. L. ; Mak, Raymond H.

Artificial intelligence (AI) has the potential to fundamentally alter the way medicine is practised. AI platforms excel in recognizing complex patterns in medical data and provide a quantitative, rather than purely qualitative, assessment of clinical conditions. Accordingly, AI could have particularly transformative applications in radiation oncology given the multifaceted and highly technical nature of this field of medicine with a heavy reliance on digital data processing and computer [...]

Cet article présente les recommandations de l'"European Society of Medical Oncology", de l'"European Oncology Nursing Society" et de l'"European Association of Neuro-Oncology" pour la prise en charge des neurotoxicités centrales et périphériques induites par une chimiothérapie chez des patients atteints d'un cancer

Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

Jordan, B. ; Margulies, A. ; Cardoso, F. ; Cavaletti, G. ; Haugnes, H. S. ; Jahn, P. ; Le Rhun, E. ; Preusser, M. ; Scotté, F. ; Taphoorn, M. J. B. ; Jordan, K.

Central and especially peripheral neurotoxicities due to systemic antineoplastic therapy are common and often dose-limiting side effects. In patients with chemotherapy-induced peripheral neurotoxicity (CIPN), recovery is in general partial with residual deficits in most patients. In these Clinical Practice Guidelines, recommendations on diagnosis, prevention and treatment of peripheral neurotoxicity and specific aspects of central neurotoxicity due to antineoplastic therapy will be given. [...]

Cet article présente les recommandations de l'"European Society for Medical Oncology" et du réseau "EURACAN" concernant le diagnostic, le traitement et le suivi d'un carcinome corticosurrénal et d'un phéochromocytome malin

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fassnacht, M. ; Assie, G. ; Baudin, E. ; Eisenhofer, G. ; Fouchardiere, C. de la ; Haak, H. R. ; de Krijger, R. ; Porpiglia, F. ; Terzolo, M. ; Berruti, A.

This updated ESMO Clinical Practice Guideline provides key recommendations on the management of adrenal cancer: -Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe -Detailed guidance on diagnosis, classification, treatment and follow-up is provided for both adrenocortical carcinoma and malignant phaeochromocytoma -Recommendations are provided in the text, including levels of evidence and grades of recommendation, where applicable -Due to [...]

Cet article présente les nouvelles catégories génomiques proposées récemment pour les lymphomes diffus à grandes cellules B puis analyse le potentiel de ces nouvelles catégories pour personnaliser les traitements

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm

Crombie, Jennifer L. ; Armand, Philippe

The clinical and molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL), even beyond the recent WHO reclassification,1 is well recognized. (For simplicity, this review will still use the term DLBCL to cover all the related WHO entities, including high-grade B-cell lymphoma [HGBL].) Yet, efforts to individualize therapy on the basis of this recognition have thus far been met with limited success.2,3 Why this may be, and why this may soon change, is the topic of this review. Recent [...]

A partir d’une revue systématique de la littérature publiée entre 2011 et 2020 (17 essais), cette étude présente les recommandations de l’American Society of Clinical Oncology concernant l’utilisation des inhibiteurs de PARP pour traiter les patientes atteintes d’un cancer de l’ovaire

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

William P. Tew, Christina Lacchetti, Annie Ellis (et al.)

PURPOSE : To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). METHODS : Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking. RESULTS : The systematic review [...]

Cet article présente une mise à jour des recommandations de l'"American Society of Clinical Oncology" concernant le traitement d'un cancer métastatique du pancréas après une première ligne thérapeutique inefficace ou non tolérée par le patient

Metastatic Pancreatic Cancer: ASCO Guideline Update

Sohal, Davendra P. S. ; Kennedy, Erin B. ; Cinar, Pelin ; Conroy, Thierry ; Copur, Mehmet S. ; Crane, Christopher H. ; Garrido-Laguna, Ignacio ; Lau, Michelle W. ; Johnson, Tyler ; Krishnamurthi, Smitha ; Moravek, Cassadie ; O’Reilly, Eileen M. ; Philip, Philip A. ; Pant, Shubham ; Shah, Manish A. ; Sahai, Vaibhav ; Uronis, Hope E. ; Zaidi, Neeha ; Laheru, Daniel

PURPOSE : The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS : ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS : One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on [...]

Menée à partir des données du registre néerlandais des cancers portant sur 2 027 patients atteints d'un cancer de la tête du pancréas ou d'un cancer péri-ampullaire, cette étude évalue l'effet du délai entre la réunion de concertation pluridisciplinaire et la pancréatoduodénectomie sur les taux de résection et la survie globale

Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes

Steen, M. W. ; van Rijssen, L. B. ; Festen, S. ; Busch, O. R. ; Groot Koerkamp, B. ; van der Geest, L. G. ; de Hingh, I. H. ; van Santvoort, H. C. ; Besselink, M. G. ; Gerhards, M. F. ; Dutch Pancreatic Cancer, Group

Background : Dutch guidelines indicate that treatment of pancreatic head and periampullary malignancies should be started within 3 weeks of the multidisciplinary team (MDT) meeting. This study aimed to assess the impact of time to surgery on oncological outcomes. Methods : This was a retrospective population‐based cohort study of patients with pancreatic head and periampullary malignancies included in the Netherlands Cancer Registry. Patients scheduled for pancreatoduodenectomy and who were [...]

Menée aux Etats-Unis à partir des données 2015-2017 portant sur 32 183 patients atteints d'un cancer du poumon, 465 chirurgiens et 209 hôpitaux, cette étude met en évidence l'absence d'association entre l'atteinte du nombre minimal de résections pulmonaires à réaliser par an (40 patients par an à l'échelle de hôpital et 20 patients par an par chirurgien) et l'amélioration des résultats intra- et post-opératoires

Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection

Farjah, Farhood ; Grau-Sepulveda, Maria V. ; Gaissert, Henning ; Block, Mark ; Grogan, Eric ; Brown, Lisa M. ; Kosinski, Andrzej S. ; Kozower, Benjamin D.

PURPOSE : We examined the relationship between short-term outcomes and hospitals and surgeons who met minimum volume thresholds for lung cancer resection based on definitions provided by the Volume Pledge. A secondary aim was to evaluate the volume-outcome relationship to determine alternative thresholds in the event the Volume Pledge was not associated with outcomes. PATIENTS AND METHODS : We conducted a retrospective study (2015-2017) using the Society of Thoracic Surgeons General Thoracic [...]